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equity in KRT in different countries are the organization of
health systems, overall health care spending, funding and
delivery models, and nature of KRT prioritization
(transplantation, hemodialysis or peritoneal dialysis, and
conservative care). Implementation of KRT programs has
the potential to exacerbate inequity unless equity is
deliberately addressed. In this review, we summarize
discussions on equitable provision of KRT in low- and
middle-income countries and suggest areas for future
research.
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Inequity is said to be present when avoidable, unfair, or
remediable differences exist among groups of people, however
defined.1 This definition recognizes that there could be dif-
ferences in the nature of health care and its delivery as long as
they can be justified in that they do not lead to differences
that systematically affect certain groups of people. Equity can
be horizontal, that is, equal treatment of equals leading toTable 1 | Examples of differences in vision on equity of care for
theoretical frameworks
Egalitarian
Availability
Should preventive care
for ESKD be present?
Yes, on the condition that it is
provided in a way that decreases
disparity for the risk of ESKD and
poor living conditions between
groups; it should be taken into
account that prevalence of ESKD
itself is distributed unequally
between groups
i
Who should organize
the preventive care?
Preferably the government, to
ensure equality; nongovernmental
organizations are acceptable if they
ensure equality
Should KRT be present? Yes, on the condition that it is
provided in a way that decreases
disparity between groups for the
risk of ESKD and of poor living
conditions
i
Who should organize KRT? Preferably the government to
ensure equality; nongovernmental
organizations are acceptable if they
ensure equality and for-profit
organizations should be avoided
How should access to
KRT be organized?
Restrictions in access are acceptable
when clear rules on who can and
who cannot apply are provided;
differences in access purely based
on group membership are
unacceptable
Re
if
Affordability
How should financing
of ESKD care be organized?
Distributive justice (obligatory
insurance organized by the
government): everybody should
contribute according to his or her
ability; everybody should receive
what he or she needs to maintain
good health
By
co
—
—
Acceptability
Should impact on non–kidney
disease aspects be taken
into account?
Yes, health care interventions
should always be assessed in
the broad context of improving
general well-being; accordingly,
impact on other disease
conditions and on social aspects
(e.g., education) should be taken
into account
Co
dif
—
—
—
ESKD, end-stage kidney disease; KRT, kidney replacement therapy.
e64equivalent outcomes, or vertical, that is, unequal but fair
treatment where inequality and/or need exists, administered
according to a fair process. The latter must be defined by
differences in the needs of populations that guide allocation
based on appropriate consideration of the principles of social
and distributive justice (from each one according to ability
and to each one according to need), including concern for the
vulnerable and the worse off, and a balance between utili-
tarianism (prioritization of interventions that provide the
greatest overall health benefit to the greatest number ofpatients with end-stage kidney disease between different
Utilitarian Libertarian
Yes, if there is proof that this
mproves health more than other
health strategies
Yes, provided it does not interfere
with personal freedom and
responsibility
The structure that can provide
preventive care with the optimal
cost–benefit ratio
Every person or structure should
have the right to organize this if
they are willing to do so
Yes, if it there is proof that this
mproves health more than other
health strategies
Yes, provided it does not interfere
with personal freedom and
responsibility
The structure that can provide
preventive care with the optimal
cost–benefit ratio
Every person or structure should
have the right to organize this if
they are willing to do so
strictions in access are acceptable
based on cost–utility differences
between individuals or groups
Everyone who can afford it should
have access
the system that maximizes
st-benefit:
When maximization at individual
level is intended, probably
a private insurance system
When maximization at society
level is intended, probably a
distributive justice system
Commutative justice (private
insurance): everybody has the
individual responsibility to ensure
financing of his or her health care
costs
st–benefit can be calculated at
ferent levels:
The individual patient: is strategy
A better than strategy B?
Across disease states: does
managing disease A vs. disease B
add more cost or benefit or both?
At society level: what is the
societal cost of managing a
disease (opportunity costs)?
At the individual level, the choice to
balance between different options
is up to the informed patient
(shared decision-making); at the
society level, there is no obligation
for an individual to take into
account the potential impact of his
or her treatment decisions on
others
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tarianism (freedom of choice and individual judgment with
minimal state or social interventions). Additional details are
presented in Table 1.
Current status and considerations on equity in ESKD
Equitable implementation of a health service such as kidney
replacement therapy (KRT) requires consideration of avail-
ability, affordability, and acceptability. The decision of
whether to set up KRT is driven by needs and demands from
the public in relation to the local environment and context to
ensure equitable service delivery for all patients. In the
following paragraphs, we explore which elements contribute
to or hinder equity in access to end-stage kidney disease
(ESKD) care and propose potential solutions or areas of
research to promote equity.
Availability
Global inequity in provision of KRT is reflected in the large
differences in the country-level prevalence of different KRT
modalities.2–5 In fact, the commonly accepted metric of
country-level “prevalence of ESKD” reflects prevalence of
treated ESKD, highlighting the between-country inequities in
access to KRT. Low- and middle-income countries (LMICs)
often lack financial, logistic, and labor force capacity to
provide KRT at scale. Simply making KRT available does not
address accessibility, which is driven by personal, family, and
geographic, as well as societal factors. The lack of pro-
fessionals trained to provide KRT is driven by a number of
factors and is addressed elsewhere.6
Financing and organization of health systems has a major
bearing on equitable access to KRT in individual countries.
Countries can be broadly grouped into 3 categories in terms
of financing of KRT: (i) predominantly public system; (ii)
mixed public–private system; and (iii) predominately private,
market-oriented system.
Low-income countries are often characterized by a low
participation of the public sector, with market forcesTable 2 | Health system-related economic data of selected count
Colombia8,10,11 Mexico9,11
Per capita gross national
income (USD)
5890 8610
Per capita health expenditure:
USD 402 462
% of GNI 6.8 5.4
% of Public expenditure 18.5 10.4
Health care budget:
% Public 76 52
% Private 24 48
% Out-of-pocket 15 40
Type of health system Predominantly public Mixed public–privat
Universal access to KRT Yes No
Restrictions on access No Yes
KRT registry Yes Transplant only
ESKD prevention program Yes No
CKD registry Yes No
CKD, chronic kidney disease; ESKD, end-stage kidney disease; GNI, gross national incom
United States dollars.
Kidney International Supplements (2020) 10, e63–e71determining access to KRT and leading to a high incidence of
out-of-pocket (OOP) expenditure. The picture is more mixed
in middle-income economies, whereas in high-income
countries KRT is funded almost exclusively through public
funds.7 At lower ranges, there is an almost linear relationship
between the gross domestic product (GDP) of a country and
KRT prevalence. However, some important differences can be
noted even between countries with equivalent wealth status,
suggesting that variations in implementation policies also
impact ESKD care delivery. For example, although Colombia
and Mexico have comparable GDPs between 5000 and 8000
USD, the proportion of government expenditure as a per-
centage of total expenditure on health varies, being 75% in
Colombia and 52% in Mexico.8–10 These discrepancies are
also evident in other regions. With similar income, the per-
centage of total expenditure on health in South Africa (40%)
is significantly lower than in Thailand (75%). Thailand and
Colombia have successfully implemented universal access to
KRT, but access remains restricted for populations in Mexico
and South Africa. As a result, OOP costs as a percentage of
total spending on health are significantly lower in Colombia
(15%) and Thailand (11%), in comparison to South Africa
(30%) and Mexico (40%)8–16 (Table 2). Some examples of the
impact of the type of national health care system on access to
ESKD treatment are presented in more detail in this section
and are summarized in Table 28–19 and Table 3.10,13,20–34
Anecdotal reports have described informal insurance mech-
anisms such as charity, informal credit, and microfinancing
for funding KRT in LMICs. Though these mechanisms reduce
financial burdens for some time, they do not fully address all
costs and might add to inequity.
Funding models determine dialysis availability. Industry is
often the driver of ESKD care provision, especially dialysis
in LMICs. It makes all necessary investments to establish
care in return for an agreed return on investment, that is,
private-public partnerships (PPPs). Limited data are avail-
able on the impact of such models on equity. In a studyries and impact on KRT provision
South Africa12–14 Thailand15,16 India17–19
5430 5950 1790
464 256 64
8.3 4.5 3.9
10.2 11 12.3
40 76 26
60 24 74
30 11 68
e Mixed public–private Mixed public–private Predominantly private
No Yes No
Yes Yes Yes
Yes HD and PD only No
No No No
No No No
e; HD, hemodialysis; KRT, kidney replacement therapy; PD, peritoneal dialysis; USD,
e65
Table 3 | Examples of health care systems and their financing
Country Health care system and financing details
Colombia Until the early 1990s, the Colombian health system was made up of 3 subsectors: (i) Social Security scheme offered to formal sector
workers; (ii) private health insurance for those able to afford it; and (iii) a tax-based financing system for those without health care
insurance. In 1994, the system changed to the current 2 major health insurance schemes: (i) a contributory regime, which is mandatory
for formal workers and those with the capacity to pay; (ii) a subsidized regime for the unemployed, informal sector workers, and the
poor.10 The contributory regime is financed by an income-based payroll tax paid partly by employees and partly by employers, whereas
the subsidized regime is financed mainly by taxation. People are free to buy additional private health insurance on top of the
contributory one. Teachers in public schools and universities, the military and police officers, and workers of the national oil company
still have special health care schemes. The Fondo de Solidaridad y Garantía pools all payroll-based contributions for health as well as
other public sources earmarked for the health sector. In 2007, the government established a high-cost subaccount, managed by a
nongovernmental organization (CAC), to pool and redistribute risk retrospectively for catastrophic conditions such as ESKD, HIV,
hemophilia, and some other diseases across the entire population.20 The main health care purchasers are EPSs, which are similar to
health maintenance organizations. EPSs manage a package of a mandatory health plan, which includes dialysis and kidney
transplantation, and public health activities such as screening for certain diseases such as hypertension, diabetes, and chronic kidney
disease. Although EPSs can either provide services directly or contract private or public providers, the private sector dominates health
care provision in Colombia, accounting for two-thirds of health expenditure by EPS in 2012. Under both the contributory and subsidized
regimes, members are allowed to choose the EPS of their preference, which results in EPSs competing for enrollees and providers
competing for inclusion in EPS networks. This is more evident in the more densely populated urban areas where competition exists
between different EPSs, but not in rural and underserved areas where it is less profitable for EPSs to set up.10 Access to KRT in Colombia
is universal, and with the implementation of CAC, the prevalence of treated ESKD increased from 445.3 pmp in 2007 to 671.5 pmp in
2016.21 However, some disparities are evident between the contributory and the subsidized regimes. In 2016, there were 32,786 patients
on KRT, with 61% being in the contributory regime. The patients in the subsided scheme were underrepresented in all types of KRT and
especially in kidney transplantation (only 18.6%).20 In spite of its success, CAC has been criticized by its lack of transparency of
reporting the financing of KRT, the equal access to treatment and the assessment of health outcomes, and its strong emphasis on
KRT rather than prevention.22
Mexico Health services in Mexico are provided through a variety of subsystems. The largest of these is the IMSS, which provides health care
services for formal workers in the private sector. The ISSSTE provides similar services for federal government employees. The military and
the national oil company have their own health care schemes. Other key institutions include the network of SHS, for those without
employment-linked insurance. After the introduction of the SP in 2004, publicly-funded health insurance extended to 50 million
Mexicans who were previously uninsured. Prior to the SP, these individuals only had access to SHS for a fee.23 Health insurance in the
social security schemes is funded through payroll contributions by the employer and the employee, with an additional federal allocation
from general taxation. Financing of the SP is based on a tripartite structure that includes contributions from 3 sources: the federal
government, state governments, and the beneficiary. The social contribution is a fixed allocation per family, which is funded entirely by
the federal government. The second element is the coresponsible contribution between the federal and state governments to redress
the differences in the level of development among states. The third component is the family contribution, which is progressive and
redistributes family income.24 The SP divides personal health services into an essential package of primary- and secondary-level
interventions, which are provided in ambulatory settings and general hospitals, and a package of high-cost tertiary-level interventions
financed through the Fondo de Proteccion contra Gastos Catastroficos.24,25 Patients and families belonging to IMSS or ISSSTE and those
with private insurance have universal access to KRT. SP does not cover ESKD treatment, except for kidney transplantation in children<18
years of age. Patients without social security must pay from their own resources for KRT, which limits their access. As a consequence,
many patients refuse dialysis, eventually abandon their treatment, or lose their kidney grafts because sustaining KRT becomes
unaffordable.26 This results in marked disparities between the insured and uninsured population, and in 2015, KRT incidence and
prevalence rates in the population with vs. without social security were 281 and 1357 vs. 130 and 200 pmp, respectively.21 In spite of the
success of the SP in expanding health insurance coverage to close to 84% of the Mexican population, its existence has been questioned
by the new federal authorities and so has the access to KRT coverage for more than one-half of the Mexican population.
South Africa Private insurance, the so-called medical schemes, is a key element of the financing system. Initially, there were few schemes restricted to
formal workers. Over time, many open schemes have developed, allowing anyone to join provided they can pay. Most care for private
insurees is provided by the private supplier sector. Private general practitioners are widespread in urban areas, and private for-profit
hospitals are available in the major cities and provincial capitals. Prices in the private sector are prohibitive for the majority of the
population, resulting in major inequities in the health care resources used by different population groups.13 To promote financial access
to public-sector health care services for vulnerable groups, user fees have been removed for all public-sector primary care services.
However, outside these services, patients face substantial fees at public-sector hospitals. An analysis of the South African public–private
mix demonstrated substantial inequities in health financing. Sixteen percent of the population is covered for all health care in the private
sector, and a further 21% of the population uses the private sector with out-of-pocket basis mainly for primary care but are likely to be
entirely dependent on the public sector for tertiary care such as KRT. The remaining 64.2% of the population is entirely dependent on the
public sector for all types of health care services, including KRT.13 Between 2013 and 2015, the prevalence of treated ESKD increased
from 167 pmp to 189 pmp, mainly due to the increased numbers of patients accessing dialysis in the private sector. In the public sector,
the prevalence of KRT remained stable around 72 pmp over the last 25 years, so the disparity in access to KRT continued to increase.27
Initially, rationing of patients for dialysis was based on informal criteria concerning eligibility for kidney transplantation. In 1997, the
National Department of Health consolidated the criteria in use to develop a formal national policy. However, of all patients with ESKD
assessed over a 15-year period, only 47% were actually accepted for KRT. The likelihood of acceptance into the program was significantly
biased in favor of patients who were employed, married, white, and younger. Almost 60% of patients were denied KRT because of social
factors related to poverty.28 Recently the Accountability for Reasonableness guidelines have been adopted by the health authorities of
the Western Cape government. They include a novel 3-tiered hierarchy of priorities, based on the likelihood of best outcomes. Although
the model’s success ensured that all ideal candidates received treatment, it failed to completely eliminate inequity, and only 25% of all
ESKD patients assessed were accepted for KRT.29 Patients in rural areas are underserved as a result of the lack of facilities and
geographical barriers. The expenses attributable to the HIV/AIDS epidemic at least partially contribute to the low level of provision of KRT
compared with the level of KRT provision in similar upper-middle-income countries.
(Continued on next page)
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Table 3 | (Continued)
Country Health care system and financing details
Thailand Extension of health insurance coverage has been pursued in Thailand since 1975. In 1975, low-income households were covered under
the publicly funded LIC scheme. Government employees and their dependents were covered with the establishment of the CSMBS in
1978. In 1981, a publicly subsidized VHC scheme was initiated by the Ministry of Public Health to cover the nonpoor informal sector.
Later in 1990, the SSS was established to provide mandatory coverage for formal-sector private employees. The major sources of funds
are from general taxation, followed by direct out-of-pocket payment, social health insurance, and private insurance premiums.30 In 2001,
UHC was implemented. The UHC scheme incorporated the existing LIC and VHC schemes and extended coverage to the 30% previously
uninsured population. All 3 groups are covered under a single fund financed by general taxation, whereas the CSMBS and the SSS still
operate their own schemes.30 The initial UHC did not include KRT because of budget impact reasons and only beneficiaries of the CSMBS
and the SSS, representing 25% of the Thai population, had access to KRT. Advocacy by nephrologists and civil society seeking equity in
access to dialysis led to the development of the “PD First” policy and marked a turning point in ESKD care in Thailand. Initially, full
reimbursement for PD was provided. However, if there was any contraindication to PD, HD costs could also be fully reimbursed. If a
patient started with PD, but because of any medical or social problems with the therapy required shifting to HD, the costs would
continue to be fully reimbursed. The indications for shifting to HD were set up by the Nephrology Society of Thailand and regional
committees are authorized to make the decisions. Over time, the policy has been revised and patients who started HD before launching
the policy are now also fully reimbursed. However, those who elect to start HD since the launch of the policy must pay the cost of the
treatment.31 The PD First policy has been successfully implemented, with an increase of the incidence and prevalence of treated ESKD
from 68.34 pmp and 419.9 pmp in 2007 to 249.06 pmp and 1072.9 pmp in 2013, respectively. By 2015, the percentage of UHC patients
on PD was 60%. The budget of the PD First policy has increased gradually to more than 220 million USD in 2017.31
India All forms of KRT are available in India but are largely restricted to big cities and private-sector hospitals. Public-sector hospitals are
overburdened with the dialysis requirement of patients with acute kidney injury and do not have the infrastructure to support chronic
outpatient dialysis.32 Few people have access to health insurance, and discontinuation of dialysis is high due to excessive out-of-pocket
costs, which are often substantially higher than monthly income, resulting in catastrophic health expenditure.33,34 As part of its agenda
to achieve UHC by 2022, the Indian government has committed to establishing at least one 8-station dialysis unit in each of its 688
districts and is offering free HD to people living below the poverty threshold. To realistically meet this demand, care models with low-
cost dialysis machines and nonphysician health workers will need to be developed.33
CAC, Cuenta de Alto Costo; CSMBS, Civil Servant Medical Benefit Scheme; EPS, Entidades Promotoras de Salud; ESKD, end-stage kidney disease; HD, hemodialysis; IMSS,
Instituto Mexicano del Seguro Social; ISSSTE, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado; KRT, kidney replacement therapy; LIC, Low-Income
Card; PD, peritoneal dialysis; pmp, per million population; SHS, Servicios Estatales de Salud; SP, Seguro Popular; SSS, Social Security Scheme; UHC, universal health care
coverage; VHC, Voluntary Health Card.
W Van Biesen et al.: Equity in provision of kidney replacement therapy I SN pub l i c a f f a i r sfrom India, introduction of free hemodialysis (HD) at point
of care delivered by a private provider under a PPP led to
year-on-year increase in uptake but was marked by poor
outcomes with over 60% dropping out within 6 months.
Males outnumbered females among those accessing dialysis
by 3:1.35 A particular feature of PPP dialysis delivery
models is a decline in utilization of peritoneal dialysis (PD).
For example, such models have decreased PD utilization in
Latin America.36 In Mexico, this model has resulted in a
considerable decrease in PD utilization in the social security
health sector, with a significant increase in HD expendi-
tures.37,38 PD was the treatment of choice (>90%) under
the Mexican Institute for Social Security (IMSS),39 whereas
the increasing capacity of private HD units established in
PPPs caused a shift to HD as a first option.26 As a conse-
quence, the number of patients on PD declined to 59% of
the dialysis population, at a higher cost (estimated at
$15,000 USD per patient per year) to the public sector.37 In
Brazil, private industries provide the bulk of KRT, resulting
in higher utilization of HD than PD (93% vs. 7% of
prevalent dialysis patients). Between 2003 and 2016, the
percentage of patients on PD in Brazil declined from 10.8%
to 6.9%.40 In Colombia, KRT is provided as part of a suite
of services that include promotion of kidney health, chronic
kidney disease (CKD) prevention, free choice of KRT, and
mandatory outcome reporting.41 Even here provision of
dialysis by the private sector led to a decline in the pro-
portion of PD patients from 36.7% to 27% over the last
decade.40 Charity organizations have tried to solve theKidney International Supplements (2020) 10, e63–e71availability issue using different approaches,42–45 but it is
unclear whether such approaches result in transparent,
equitable, and sustainable access to KRT.
One way by which some countries have attempted to
achieve equity in access to KRT in the face of shortages is
through rationing,46,47 that is, restricting access of some
people for whom this treatment may be potentially useful.
Rationing can be introduced at the level of the policy makers,
health systems managers, clinicians-providers, or individual
patients. Several models of rationing have been proposed,
using a mix of evidence-based inputs (disease epidemiology,
population and health system characteristics, comparative
cost-effectiveness, and impact on outcomes) and process
changes leading to demand and supply-side strategies to
regulate access.48 To achieve optimal outcomes, such ra-
tioning schemes require stewardship and need continuous
monitoring to assess their impact on equity and efficiency of
KRT.
The impact of geography on availability. Major geographic
inequities have been described from almost all LMICs, with
those living in urban areas enjoying an advantage. Navigating
vast distances between neighborhoods and dialysis facilities is
compounded by lack of sufficient and affordable trans-
portation, infrastructure, and overpopulation in the larger
cities. In Brazil, 50% of the dialysis population is concentrated
in 3 highly urbanized southern states—Sao Paulo, Rio de
Janeiro, and Minas Gerais—whereas access to KRT among
those living in the rural north is very low. Not surprisingly,
63.5% of Brazilian nephrologists are located in the states withe67
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a decentralized approach to KRT is critical. Investing in the
education of local people to perform basic aspects of care
would benefit the broad community and increase equity.
Training programs tend to be overspecialized and do not al-
ways deliver knowledge relevant for the prevalent circum-
stances. This may exacerbate inequity as well-trained
personnel migrate to big cities or abroad to be able to apply
their new skills. Training programs, such as those delivered
through the International Society of Nephrology’s programs,
should support the use of locally available material and
expertise rather than introduce complex technical procedures
that require external expertise and drain funds to foreign
providers rather than supporting the local economy. Prefer-
ence should be given to hands-on clinical training, preferably
within the physician’s own region, to increase the relevance
and utility of the training to the physician’s home country and
to reduce costs and the risk of “brain drain.”50
In terms of sustainability and efficiency, the value of online
training to enhance knowledge and skills of health workers on
management with advanced CKD including ESKD and its
impact on inequity needs to be assessed. In the short term,
such programs should increase awareness and support pre-
vention. In the mid-term, they should allow improved quality
of therapeutic interventions in well-defined cases, such as,
KRT for acute kidney injury. In the long term, they should be
able to participate in advocacy and governance to facilitate
comprehensive care for the patient with ESKD in collabora-
tion between industry, research groups, clinical experts, and
patient groups.
Use of digital technologies has great potential in contrib-
uting to equitable dissemination of knowledge to health care
professionals and delivery of quality care to patients, from
prevention and care of early stage CKD to management of
patients with ESKD. When developing such e-health devices,
one should take care that the tools align with the actual need
of the target group, rather than create new needs.51 Caution
should be taken to ensure that these tools reach the ones with
the worst access to health care to prevent them getting even
more disadvantaged.52 Overall, available evidence on e-health
applications directly oriented toward CKD patients is incon-
clusive.53 Evaluation and certification of patient-oriented apps
might prove difficult for several reasons.54
Affordability
In LMICs, affordability is clearly a major issue contributing to
inequity. The WHO estimates that a minimal health care
spending per person of 271 USD (range, 74–984 USD), or
allocation of 7.5% (2.1%–20.5%) of GDP on health care is
required to meet the health-related Sustainable Development
Goals.55 As GDP is not equitably distributed across the
population, inequities in health care access can result even
when a sufficient average budget per capita is achieved.
It has been estimated that about 188 million people
experience catastrophic health expenditure annually as a
result of kidney diseases across LMICs, the greatest of anye68disease group.56 OOP costs are highest in the poorest coun-
tries. In most, if not all LMICs, the yearly cost of KRT per
capita substantially exceeds the GDP, making it cost-
ineffective by definition.2,57 Mere availability of dialysis,
without sustainable funding models, leads to the financial
bankruptcy of families, often without the commensurate
expected health benefit.4 This is more problematic in settings
where cultural beliefs enforce that everything possible should
be done to save a life. Optimization of equity requires that if
KRT is provided, locally appropriate funding models are
developed to eliminate all possible sources of unreasonable
OOP expenditure. Successful models have been implemented
in LMICs such as Colombia and Thailand.31,41 In many
countries, allocating sufficient funds to appropriate health
care programs is more a political than a financial decision.
For example, with a higher proportion of GDP allocated to
public health, Colombia with a lower GDP has achieved
universal access to KRT, whereas Mexico has not, despite a
higher GDP but lower allocation to public health. As
result, KRT-related OOP expenses are much lower in
Colombia.7,10,11,58
Ideally, sustainable KRT care models should be coupled
with essential prevention, primary and secondary health care
services, and access to essential medicines.2,46 KRTmodalities
should be prioritized in such a manner as to promote equity.
Kidney transplantation, despite being the cheapest option
with greatest health benefits to the most who receive it, is
poorly established in many LMICs.59 Similarly, health tech-
nology assessment has repeatedly shown that PD is cheaper
than HD to the health system while providing equivalent
health benefits, but PD is not prioritized either because of
lack of understanding of these principles or pressures from
interest groups. In some countries, PD is expensive because of
the need to import foreign-made consumables, compounded
by imposition of import duties and unofficial charges. All
these costs are passed on to the consumer, which is not always
the case for infrastructure costs associated with HD.60 These
data have repeatedly shown that local manufacturing of PD
bags brings down costs. Lack of well-designed health eco-
nomic studies have also perpetuated the myth of lower cost of
HD in many LMICs. A recent study from India showed that
the total cost of HD to the system was 4 to 8 times higher than
previously estimated reports, making it far more expensive
than PD, contrary to the currently accepted narrative that PD
is more expensive than HD.61 Finally, supportive care services,
increasingly considered integral to holistic ESKD care de-
livery, are almost nonexistent in LMICs.62
Some of the costs incurred with HD flow partially back to
the community as payment for goods and services. The
overall cost to the society goes down through increased local
manufacturing that prevents drain of economic means to
other countries and creation of local jobs. As such, setting up
KRT may indirectly contribute to social justice.
Affordability depends not only on “how to get more
money” (revenue) but also on “how to spend the money.” The
latter requires consideration of governance and organizationalKidney International Supplements (2020) 10, e63–e71
Table 4 | Gaps in knowledge and need for further research
Questions to address Process
What proportion of the total health care budget can a country spend on ESKD care relative
to the desired level of health status, available technology, and costs without enhancing
inequity?
Health science evaluation
What is the economic and societal return of money invested in KRT care by way of
promoting local manufacturing and creating jobs, skills, trade, and knowledge?
Societal and economic evaluation
What is the best way of comparing HD and PD in terms of their impact on equity of care
provision and how can this be implemented?
Health technology assessment
What are the minimal essential requirements to safely implement a transplantation
program in an equitable way in LMICs?
Scientific medical evaluation, systematic review, Delphi
Which models are in use for implementation of ESKD care in LMICs; what were the results;
which factors (modifiable and nonmodifiable) determined success or failure and their
impact on equity? (Consider governmental vs. external programs, public vs. private,
prevention vs. curing, mixed models.)
Systematic review, epidemiology, health care sciences
Is there inequity in access to provided care and outcome based on sex? Systematic review; epidemiology
ESKD, end-stage kidney disease; HD, hemodialysis; KRT, kidney replacement therapy; LMICs, low- and middle-income countries; PD, peritoneal dialysis.
W Van Biesen et al.: Equity in provision of kidney replacement therapy I SN pub l i c a f f a i r sfactors. Some countries, such as Thailand, undertook a
dedicated in-depth health technology assessment of the needs
and possibilities with regard to ESKD care before making
decisions on how to implement a KRT program.63 When
dialysis cannot be provided to all individuals, guidelines based
on a transparent decision-making, taking into account the
individual patient’s circumstances, should be developed to
optimize use of this limited resource. In South African state
hospitals, dialysis is only offered to those who are eligible to
and consent to receiving a transplant when offered.29 In
Thailand, a patient with ESKD can be treated for free by PD,
whereas those who decline the offer and choose HD will not
get financial support.3,31
Acceptability
Acceptability implies consideration of ethical and societal
standards. The WHO specifically warns against “vertical
health silos,” whereby basic needs of the population are
neglected while implementing expensive health care tech-
nologies.64 It is a matter of debate whether KRT should be
developed in regions where access to essential health services
is limited, because it likely exacerbates overall health inequity.
However, it can be argued that in absence of oversight, the
private sector will identify this market gap and introduce or
expand KRT, especially dialysis. This will exacerbate inequity
even more among those with ESKD because a proportion will
always have the financial means to access KRT, whereas the
poor will end up even worse off on account of having
incurred catastrophic OOP expenses.
Making appropriate decisions that address all issues that
help proper allocation of resources and eliminate inequity in
KRT delivery requires continuous access to data and ongoing
research. Registries provide this important service. It is
imperative that all countries allocate resources for data
collection and quality monitoring. In addition to standard
treatment-related parameters, registries should collect data on
parameters of discrimination (e.g., social, education, sex,
ethnicity, migrant status, place of residence) and comorbidity
to ensure that the system does not exacerbate inequities.Kidney International Supplements (2020) 10, e63–e71Table 4 lists additional knowledge gaps that need to be
addressed through context-specific research.
Conclusion
Whereas provision of care for patients in LMICs is a challenge
in itself, it becomes even more difficult when considerations
of equity are taken into account. Prevention strategies should
be installed as a first measure as they yield the most cost-
benefit on individual and societal levels. When implement-
ing a KRT program, we should be vigilant to avoid increasing
disparity in well-being between groups. The actual data to
make evidence-based decisions on if, when, how, and by
whom KRT programs should be implemented are lacking,
and research in that area is urgently needed.
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